Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bio-Rad Laboratories

241.02
+8.473.64%
Post-market: 241.020.00000.00%16:07 EDT
Volume:258.27K
Turnover:62.17M
Market Cap:6.56B
PE:-3.13
High:243.75
Open:233.09
Low:233.09
Close:232.55
Loading ...

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Business Wire
·
05 Feb

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
05 Feb

Can-Fite BioPharma to Present Namodenoson at Upcoming BIO CEO Conference

TIPRANKS
·
05 Feb

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
05 Feb

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

GlobeNewswire
·
05 Feb

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Zacks
·
04 Feb

GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference

NewMediaWire
·
04 Feb

RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating

MT Newswires Live
·
04 Feb

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

PR Newswire
·
04 Feb

Azitra, Inc. to Present at the BIO CEO & Investor Conference

PR Newswire
·
03 Feb

Press Release: SIMPLY SOLVENTLESS ANNOUNCES OVER SUBSCRIPTION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING TO $6.0 MILLION & EXPECTED DELTA 9 BIO-TECH CLOSING DATE OF FEBRUARY 7, 2025

Dow Jones
·
03 Feb

Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference

GlobeNewswire
·
03 Feb

Reviva to Participate in the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
30 Jan

Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability

NewMediaWire
·
29 Jan

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Insider Monkey
·
29 Jan

Press Release: Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Dow Jones
·
28 Jan

Strong week for Bio-Rad Laboratories (NYSE:BIO) shareholders doesn't alleviate pain of three-year loss

Simply Wall St.
·
28 Jan

3 Altcoins That Reached All-Time Low Today — January 27

BE[IN]CRYPTO
·
28 Jan

BIO-UV Group Launches Capital Increase to Fund Growth Initiatives

TIPRANKS
·
24 Jan

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

GlobeNewswire
·
23 Jan